The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Open accessAbstract
Down syndrome (DS) is the most frequent genetic cause of intellectual disability characterized by the presence of three copies of chromosome 21 (Chr21). Individuals with DS have sufficient neuropathology for a diagnosis of Alzheimer's disease (AD) after the age of 40years. The aim of our study is to gain new insights in the molecular mechanisms impaired in DS subjects that eventually lead to the development of dementia. We evaluate the PI3K/Akt/mTOR axis in the frontal cortex from DS cases (under the age of 40years) and DS with AD neuropathology compared with age-matched controls (Young and Old). The PI3K/Akt/mTOR axis may control several key pathways involved in AD that, if aberrantly regulated, affect amyloid beta (Aβ) deposition and tau phosphorylation. Our results show a hyperactivation of PI3K/Akt/mTOR axis in individuals with DS, with and without AD pathology, in comparison with respective controls. The PI3K/Akt/mTOR deregulation results in decreased autophagy, inhibition of IRS1 and GSK3β activity. Moreover, our data suggest that aberrant activation of the PI3K/Akt/mTOR axis acts in parallel to RCAN1 in phosphorylating tau, in DS and DS/AD. In conclusion, this study provides insights into the neuropathological mechanisms that may be engaged during the development of AD in DS. We suggest that deregulation of this signaling cascade is already evident in young DS cases and persist in the presence of AD pathology. The impairment of the PI3K/Akt/mTOR axis in DS population might represent a key-contributing factor to the neurodegenerative process that culminates in Alzheimer-like dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These oxidatively modified, and likely dysfunctional, proteins include ones associated with altered glucose metabolism, mTOR signaling (including inhibited autophagy and increased insulin resistance), and the proteostasis network42,61,62,65,66.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the abnormally high level of mTOR activation seen in the brains of DS mouse models (Iyer et al., 2014;Perluigi et al., 2014) and in DS fibroblasts (Bordi et al., manuscript submitted)”
From Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) (2019) · cites this paper as Perluigi et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our findings support a hyperactivated AKT/mTOR/p70S6K axis with IRS1 inhibition in humans with DS‐AD. 7 , 9 , 59”
The cited source says what the claim attributes to it.
In the citing paper
“Higher mTORC1/S6K activity in muscle of older mice, rats and humans is associated with sarcopenia 97–101, and in brain is associated with Alzheimer’s disease 101–105.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism of activation of protein kinase B by insulin and IGF‐1.
Alessi, D. R., Andjelković, M., Caudwell, B., Cron, P. D., MORRICE, N. A., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,014
Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation
Gual, P., Le Marchand-Brustel, Y., & Tanti, J.-F. (2005) · Biochimie · doi:10.1016/j.biochi.2004.10.019 · Cited by 912 · cited 1×
“This signaling cascade is finely regulated by a negative feedback mechanism that suppresses Akt activity in case of a permanent activation of mTOR/p70S6K signal [52] [53] [54].”
Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 849
Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
Research works printed but not linked: 1
- Lovestone, 1997, The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes, Neuroscience, 78, 309
Cited by
Sorted by citations
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Self-citationHeras-Sandoval, D., Pérez-Rojas, J. M., Hernández-Damián, J., & Pedraza-Chaverri, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.019 · Cited by 1,091
Butterfield, D. A., Swomley, A. M., & Sultana, R. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5027 · Cited by 526
Self-citationButterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
Self-citationMolecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz, A., Zmorzyńska, J., & Jaworski, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 405
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Self-citationTargeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
mTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 381
Tramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
Self-citationPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Self-citationMammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Domenico, F. D., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 313
Marzia Perluigi, A., Domenico, F. D., & Butterfield, D. A. (2023) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 322
Self-citationMetabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease
Yan, X., Hu, Y., Wang, B., Wang, S., & Zhang, X. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.530219 · Cited by 230
Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99)
Jiang, Y., Sato, Y., Im, E., Berg, M., Bordi, M., Darji, S., Kumar, A., Mohan, P. S., Bandyopadhyay, U., Diaz, A., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0578-19.2019 · Cited by 166
Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
Lloret, A., Fuchsberger, T., Giraldo, E., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.028 · Cited by 135
Bordi, M., Darji, S., Sato, Y., Mellén, M., Berg, M. J., Kumar, A., Jiang, Y., & Nixon, R. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1752-5 · Cited by 124
Marzia Perluigi, A., Domenico, F. D., Barone, E., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.04.025 · Cited by 126
Self-citationIdentification of a DNA methylation signature in blood cells from persons with Down Syndrome
Bacalini, M. G., Gentilini, D., Boattini, A., Giampieri, E., Pirazzini, C., Giuliani, C., Fontanesi, E., Scurti, M., Remondini, D., Capri, M., et al. (2014) · Aging · doi:10.18632/aging.100715 · Cited by 122
Amyloid-beta and tau protein beyond Alzheimer’s disease
Abyadeh, M., Gupta, V., Paulo, J. A., Mahmoudabad, A. G., Shadfar, S., Mirshahvaladi, S., Gupta, V. B., Nguyen, C. T. O., Finkelstein, D. I., You, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.386406 · Cited by 126
Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6759 · Cited by 114
Self-citationKipanyula, M. J., Kimaro, W. H., & Etet, P. F. S. (2016) · Journal of Aging Research · doi:10.1155/2016/5081021 · Cited by 114
López-Gambero, A. J., Sanjuan, C., Serrano-Castro, P. J., Suárez, J., & de Fonseca, F. R. (2020) · Biomedicines · doi:10.3390/biomedicines8090295 · Cited by 114
Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome
Tramutola, A., Lanzillotta, C., Barone, E., Arena, A., Zuliani, I., Mosca, L., Blarzino, C., Butterfield, D. A., Marzia Perluigi, A., & Domenico, F. D. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0133-9 · Cited by 102
Self-citationDierssen, M., Fructuoso, M., de Lagrán, M. M., Marzia Perluigi, A., & Barone, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00670 · Cited by 106
Self-citationBarone, E., Di Domenico, F., Cassano, T., Arena, A., Tramutola, A., Lavecchia, M. A., Coccia, R., Butterfield, D. A., & Perluigi, M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.012 · Cited by 100
Self-citationDi Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., & Butterfield, D. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.009 · Cited by 89
Self-citationBiliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease
Barone, E., Tramutola, A., Triani, F., Calcagnini, S., Di Domenico, F., Ripoli, C., Gaetani, S., Grassi, C., Butterfield, D. A., Cassano, T., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1231-5 · Cited by 86
Self-citationMarzia Perluigi, A., Barone, E., Domenico, F. D., & Butterfield, D. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.005 · Cited by 86
Self-citationBertram, S., Brixius, K., & Brinkmann, C. K. (2016) · Endocrine · doi:10.1007/s12020-016-0976-8 · Cited by 89
Di Domenico, F., Pupo, G., Mancuso, C., Barone, E., Paolini, F., Arena, A., Blarzino, C., Schmitt, F. A., Head, E., Butterfield, D. A., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141254 · Cited by 75
Self-citationTriplett, J. C., Tramutola, A., Swomley, A. M., Kirk, J. M., Grimes, K. M., Hardell, K. N. L., Orr, M. E., Rodriguez, K. A., Cai, J., Klein, J. B., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.002 · Cited by 73
Self-citationBrain insulin resistance triggers early onset Alzheimer disease in Down syndrome
Tramutola, A., Lanzillotta, C., Di Domenico, F., Head, E., Butterfield, D. A., Perluigi, M., & Barone, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104772 · Cited by 73
Self-citationTargeting Mitochondria in Alzheimer Disease: Rationale and Perspectives
Lanzillotta, C., Domenico, F. D., Marzia Perluigi, A., & Butterfield, D. A. (2019) · CNS Drugs · doi:10.1007/s40263-019-00658-8 · Cited by 75
Self-citationTargeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.
Tramutola, A., Lanzillotta, C., & Di Domenico, F. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1244482 · Cited by 69
Self-citationDomenico, F. D., Tramutola, A., Barone, E., Lanzillotta, C., Defever, O., Arena, A., Zuliani, I., Foppoli, C., Iavarone, F., Vincenzoni, F., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101162 · Cited by 69
Self-citationFranz, D. N., & Capal, J. K. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0596-2 · Cited by 62
The burden of trisomy 21 disrupts the proteostasis network in Down syndrome
Aivazidis, S., Coughlan, C. M., Rauniyar, A. K., Jiang, H. L., Liggett, L. A., Maclean, K. N., & Roede, J. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176307 · Cited by 62
Xu, J., Huai, Y., Meng, N., Dong, Y., Liu, Z., Qi, Q., Hu, M. C., Fan, M., Jin, W., & Lv, P. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2328-3 · Cited by 62
The Implications of Autophagy in Alzheimer’s Disease
Hamano, T., Hayashi, K., Shirafuji, N., & Nakamoto, Y. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181004143432 · Cited by 57
Lee, H.-K., Kwon, B., Lemere, C. A., de la Monte, S., Itamura, K., Ha, A. Y., & Querfurth, H. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161029 · Cited by 57
Perspectives on Oxidative Stress in Alzheimer’s Disease and Predictions of Future Research Emphases
Butterfield, D. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179912 · Cited by 57
Self-citationDown Syndrome iPSC-Derived Astrocytes Impair Neuronal Synaptogenesis and the mTOR Pathway In Vitro
Araujo, B. H. S., Kaid, C., De Souza, J. S., Gomes da Silva, S., Goulart, E., Caires, L. C. J., Musso, C. M., Torres, L. B., Ferrasa, A., Herai, R., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0818-6 · Cited by 56
Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism
Barone, E., Arena, A., Head, E., Butterfield, D. A., & Marzia Perluigi, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.009 · Cited by 55
Self-citationTriani, F., Tramutola, A., Domenico, F. D., Sharma, N. K., Butterfield, D. A., Head, E., Marzia Perluigi, A., & Barone, E. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.005 · Cited by 53
Self-citationCathepsin D as a therapeutic target in Alzheimer’s disease
Domenico, F. D., Tramutola, A., & Perluigi, M. (2016) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2016.1252334 · Cited by 48
Self-citationTramutola, A., Di Domenico, F., Barone, E., Arena, A., Giorgi, A., di Francesco, L., Schininà, M. E., Coccia, R., Head, E., Butterfield, D. A., et al. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6686 · Cited by 49
Self-citationChu, F., Li, K., Li, X., Xu, L., Huang, J., & Yang, Z. R. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03167-z · Cited by 50
Lanzillotta, C., Tramutola, A., Di Giacomo, G., Marini, F., Butterfield, D. A., Di Domenico, F., Perluigi, M., & Barone, E. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.042 · Cited by 47
Self-citationHan, K., Jia, N., Zhong, Y., & Shang, X. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26452 · Cited by 47
Shen, H., Zhang, J., Zhang, Y., Qinchao, F., Wang, H., Li, G., Jiang, W., & Li, X. (2019) · Gene · doi:10.1016/j.gene.2019.02.044 · Cited by 45
Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2
Buttari, B., Tramutola, A., Rojo, A. I., Chondrogianni, N., Saha, S., Berry, A., Giona, L., Miranda, J. P., Profumo, E., Davinelli, S., et al. (2025) · Biomolecules · doi:10.3390/biom15010113 · Cited by 49
Self-citationLanzillotta, C., Zuliani, I., Tramutola, A., Barone, E., Blarzino, C., Folgiero, V., Caforio, M., Valentini, D., Villani, A., Locatelli, F., et al. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101892 · Cited by 46
Self-citationRapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down's syndrome
Andrade‐Talavera, Y., Benito, I., Casañas, J. J., Moreno, A. R., & Montesinos, M. L. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.005 · Cited by 42
Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology
Rosenberger, A. F. N., Hilhorst, R., Coart, E., Barrado, L. G., Naji, F., Rozemüller, A. J. M., van der Flier, W. M., Scheltens, P., Hoozemans, J. J. M., & van der Vies, S. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150429 · Cited by 44
Levy, J., LaFlamme, C. W., Tsaprailis, G., Crynen, G. C., & Page, D. T. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.012 · Cited by 42
Tramutola, A., Pupo, G., Di Domenico, F., Barone, E., Arena, A., Lanzillotta, C., Broekaart, D., Blarzino, C., Head, E., Butterfield, D. A., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151105 · Cited by 40
Self-citationBeirami, E., Oryan, S., Tamijani, S. M. S., Ahmadiani, A., & Dargahi, L. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26398 · Cited by 40
Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease
Zhao, Y., Zhang, Y., Zhang, J., Zhang, X., & Yang, G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200114163636 · Cited by 40
Tramutola, A., Lanzillotta, C., Arena, A., Barone, E., Marzia Perluigi, A., & Domenico, F. D. (2015) · Neurodegenerative Diseases · doi:10.1159/000441419 · Cited by 39
Self-citationPoly-ubiquitin profile in Alzheimer disease brain
Tramutola, A., Triani, F., Domenico, F. D., Barone, E., Cai, J., Klein, J. B., Marzia Perluigi, A., & Butterfield, D. A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.07.006 · Cited by 38
Self-citationModeling Down syndrome in animals from the early stage to the 4.0 models and next
Moreno, M. D. M. M., Brault, V., Birling, M., Pavlovic, G., & Hérault, Y. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2019.08.001 · Cited by 35
Consequences of chromosome gain: A new view on trisomy syndromes
Krivega, M., Stiefel, C. M., & Štorchová, Z. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.10.014 · Cited by 40
Zaki, M. E., El-Bassyouni, H. T., Tosson, A. M. S., Youness, E. R., & Hussein, J. (2016) · Jornal de Pediatria · doi:10.1016/j.jped.2016.04.012 · Cited by 38
Xu, J., Qi, Q., Lv, P., Dong, Y., Jiang, X., & Liu, Z. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198371 · Cited by 36
Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules
Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 36
Copine1 regulates neural stem cell functions during brain development
Kim, T., Sung, S., Yoo, J. C., Park, J., Yi, G.-S., Heo, J. Y., Lee, J.-R., Kim, N. S., & Lee, D. Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.167 · Cited by 34
Astrocytes in Down Syndrome Across the Lifespan
Ponroy Bally, B., & Murai, K. K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.702685 · Cited by 35
Perluigi, M., Picca, A., Montanari, E., Calvani, R., Marini, F., Matassa, R., Tramutola, A., Villani, A., Familiari, G., Domenico, F. D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12499 · Cited by 35
Self-citationRvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome
Hamlett, E. D., Hjorth, E., Ledreux, A., Gilmore, A., Schultzberg, M., & Granholm, A. C. (2020) · Glia · doi:10.1002/glia.23779 · Cited by 34
The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases
Morris, G., Walder, K. R., Carvalho, A. F., Tye, S. J., Lucas, K., Berk, M., & Maes, M. H. J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.017 · Cited by 33
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Yamini, P., Ray, R. S., Yadav, S., Dhaliwal, J., Yadav, M., Kondepudi, K. K., & Chopra, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173402 · Cited by 32
Developmental Neuropathology and Neurodegeneration of Down Syndrome: Current Knowledge in Humans
Hasina, Z., Wang, N., & Wang, C. C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.877711 · Cited by 36
Entorhinal cortex stimulation induces dentate gyrus neurogenesis through insulin receptor signaling
Ronaghi, A., Zibaii, M. I., Pandamooz, S., Nourzei, N., Motamedi, F., Ahmadiani, A., & Dargahi, L. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.11.011 · Cited by 30
Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?
Barone, E., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.013 · Cited by 30
Self-citationLife and death in the hippocampus: What's bad?
Santos, V. R., de Melo, I. S., Pacheco, A. L. D., & de Castro, O. W. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.106595 · Cited by 29
Xu, Z.-J., Li, Q., Ding, L., Shi, H.-H., Xue, C., Mao, X., Wang, Y., & Zhang, T. (2021) · Food & Function · doi:10.1039/d1fo00286d · Cited by 30
Delikkaya, B., Moriel, N., Tong, M., Gallucci, G. M., & de la Monte, S. M. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.03.004 · Cited by 29
The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome
Zuliani, I., Lanzillotta, C., Tramutola, A., Francioso, A., Pagnotta, S. E., Barone, E., Marzia Perluigi, A., & Domenico, F. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00978-4 · Cited by 29
Self-citationMartínez‐Cué, C., & Rueda, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186906 · Cited by 26
de la Monte, S. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230555 · Cited by 28
Ketamine: A Neglected Therapy for Alzheimer Disease
Smalheiser, N. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00186 · Cited by 30
Martín‐Sánchez, A., González‐Pardo, H., Alegre-Zurano, L., Castro‐Zavala, A., López-Taboada, I., Valverde, O., & Conejo, N. M. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110508 · Cited by 25
Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?
de la Monte, S. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240069 · Cited by 28
Yin, P., Wang, S., Wei, Y., Wang, X., Zhang, J., Yin, X., Feng, J., & Zhu, M. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190682 · Cited by 24
Bridging the age spectrum of neurodegenerative storage diseases
Boland, B., & Platt, F. M. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.009 · Cited by 24
Fanoudi, S., Hosseini, M., Alavi, M. S., Boroushaki, M. T., Hosseini, A., & Sadeghnia, H. R. (2018) · EXCLI journal · doi:10.17179/excli2018-1626 · Cited by 25
Redox imbalance and metabolic defects in the context of Alzheimer disease
Domenico, F. D., Lanzillotta, C., & Marzia Perluigi, A. (2024) · FEBS Letters · doi:10.1002/1873-3468.14840 · Cited by 22
Babygirija, R., Sonsalla, M. M., Mill, J., James, I., Han, J. H., Green, C. L., Calubag, M. F., Wade, G., Tobon, A., Michael, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49589-z · Cited by 22
Lanzillotta, C., Zuliani, I., Vasavda, C., Snyder, S. H., Paul, B. D., Marzia Perluigi, A., Domenico, F. D., & Barone, E. (2020) · Antioxidants · doi:10.3390/antiox9080671 · Cited by 23
Self-citationEndosome Dysregulation in Down Syndrome: A Potential Contributor to Alzheimer Disease Pathology
Filippone, A., & Praticò, D. (2021) · Annals of Neurology · doi:10.1002/ana.26042 · Cited by 20
Bhattamisra, S. K., Shin, L. Y., Saad, H. I. B. M., Rao, V., Candasamy, M., Pandey, M., & Choudhury, H. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200518102130 · Cited by 18
Lanzillotta, C., Rataj-Baniowska, M., Prestia, F., Sette, C., Nalesso, V., Marzia Perluigi, A., Barone, E., Duchon, A., Tramutola, A., Hérault, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106523 · Cited by 21
Self-citationAKT Hyperphosphorylation and T Cell Exhaustion in Down Syndrome
Peeters, D., Pico‐Knijnenburg, I., Wieringa, D., Rad, M., Cuperus, R., Ruige, M., Froeling, F. M. J. A., Zijp, G. W., van der Burg, M., & Driessen, G. J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.724436 · Cited by 17
Kaur, G., Gauthier, S. A., Pérez‐González, R., Pawlik, M., Singh, A. B., Cosby, B., Mohan, P. S., Smiley, J. F., & Levy, E. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.025 · Cited by 17
Mathkour, M., Hanna, J., Ibrahim, N., Scullen, T. A., Kilgore, M. D., Werner, C., Cormier, I., Spencer, P., Keen, J. R., & Bui, C. J. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106404 · Cited by 17
Ren, J., Xiang, B., Xueling, L., Han, X., Yang, Z., Zhang, M., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36470 · Cited by 16
Urbano‐Gámez, J. D., Benito, I., Casañas, J. J., & Montesinos, M. L. (2021) · Molecular Brain · doi:10.1186/s13041-021-00795-6 · Cited by 16
Metadata
- Authors
- Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F.
- Affiliations
- Sapienza University of Rome (IT)
- University of Kentucky (US)
- ORCID
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 1842
- Issue
- 7
- Pages
- 1144-1153
- ISSN
- 0925-4439 (ISSN-L)
- PMC
- PMC4062876
- OpenAlex
- W2158742765
- Cited by
- 155
- References
- 77
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 15 · 2023: 10 · 2022: 11 · 2021: 15 · 2020: 16 · 2019: 16 · 2018: 11 · 2017: 16 · 2016: 13 · 2015: 15 · 2014: 5
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- PRIN2009
- NIH (A6-05119)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Aging (1RO1HD064993-01)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- Down syndrome, PI3K/AKT/mTOR pathway, Alzheimer's disease, frontal cortex, autophagy, IRS-1, GSK3β, RCAN1, tau phosphorylation, amyloid-beta, intellectual disability, dementia
- MeSH terms
- Adult, Alzheimer Disease, Autophagy, DNA-Binding Proteins, Down Syndrome, Female, Frontal Lobe, Humans, Male, Middle Aged, Muscle Proteins, Phosphorylation, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Phosphatidylinositol 3-Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, Insulin Receptor Substrate Proteins, Young Adult, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
